Profusa shares surge 32.89% premarket after launching Lumee tissue oxygen monitoring for CRO market.

Profusa (NASDAQ: PFSA) surged 32.89% in premarket trading following the announcement of its commercial launch of the Lumee tissue oxygen monitoring system for healthcare research, targeting the $47.9 billion CRO market. The company began generating immediate service-based revenue by offering research-use-only kits and a service-enabled platform to contract research organizations, enabling real-time tissue oxygenation data for drug development and translational research. The initiative aligns with growing demand for predictive biological data in pharmaceutical R&D, with the CRO market projected to grow at a 7% CAGR to $91.2 billion by 2034. Profusa also appointed Sean Givens, a seasoned industry executive, to lead commercialization, reinforcing confidence in the company’s ability to capitalize on this high-growth segment. The launch underscores Profusa’s expansion into a lucrative market with near-term revenue potential, driving the sharp premarket rally.